f-652
Recombinant proteinexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02655510)
Timeline
Indications
Mechanism of action
- Interleukin-22Supplementation
IL22 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- f-652
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07060638 | Phase 2 | Oct 31, 2025 | Indiana University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT05205668 | Phase 2 | Mar 31, 2022 | EVIVE Biotechnology |
| NCT04498377 | Phase 2 | Dec 31, 2020 | EVIVE Biotechnology, Tulane University |
| NCT02655510 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Hennepin Healthcare, Indiana University, Mayo Clinic, Virginia Commonwealth University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EVIVE Biotechnology | For profit | 2 | 2 | 1 | 2020 |
| Indiana University | Academic/Hospital | 2 | 1 | 1 | 2016 |
| Hennepin Healthcare | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2016 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 0 | 1 | 2025 |
| Tulane University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1